Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
77.01
+0.50 (+0.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Hope for Haiti Kicks Off Fourth Annual Hike for Haiti Challenge Campaign to Provide Access to Education and Public Health
April 01, 2022
Feel-good global movement supported by high-profile ambassadors and brands helping to fund organization's $12M plan for school rebuilding and rehabilitation following the devastating 7.2 magnitude...
Via
Newswire.com
Advocating for Black Women With Triple-Negative Breast Cancer: Ricki's Story
April 01, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Claflin University's Deeply Rooted Commitment to Social Justice
March 30, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
March 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Channeling Her Passion to Spread Awareness About TNBC: LaToya's Journey
March 25, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Opinion: Searching for the Next Generation of Sustainable Health Care
March 22, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Exposures
COVID-19
An Open Letter on Ukraine From Daniel O'Day, Chairman & CEO
March 18, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Opinion: Why Corporate Philanthropy Must Stand Against Stigma
March 15, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead, Orbsen, and Others
March 10, 2022
Continue reading "Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead,...
Via
Get News
Crohn’s Disease Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – UCB, Abbvie, Genetech, Gilead, Celgene, Millennium Pharma, and Others
March 10, 2022
Continue reading "Crohn’s Disease Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – UCB, Abbvie, Genetech, Gilead, Celgene, Millennium Pharma, and...
Via
Get News
Opinion: Building an Inclusive World Through Sports, Art, and Culture
March 10, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Topics
LGBTQ
Exposures
Diversity
Keto Benefits And Benefits of Drinking Ketones.
March 08, 2022
Via
Marketers Media
Congratulations to Taiyin Yang, EVP, for Being Elected to the 2022 Class of the National Academy of Engineering.
March 08, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Mark Dresser Elected First Openly-LGBTQ+ President of American Society for Clinical Pharmacology and Therapeutics
March 04, 2022
SOURCE: Gilead Sciences
Via
3BL Media
We're Proud to Have Supported a Special Issue of Tuskegee University's Journal of Healthcare, Science, and the Humanities
March 02, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Keto Vs Low Carb – Intermittent Fasting Vegan Diet For Weight Loss Site Relaunch
March 01, 2022
Via
Marketers Media
Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity (Black Enterprise)
February 24, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Understanding Hepatitis D: 4 Questions With Professor Maria Buti
February 22, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Charting a Career to Help Reduce Health Inequity: Porscha's Story
February 18, 2022
SOURCE: Gilead Sciences
Via
3BL Media
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
February 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Invests in Research for COVID-19 Treatments for All Ages
February 16, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Exposures
COVID-19
Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022
February 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults
February 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
February 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Ending HIV-Related Stigma in the Southern United States: Gina's Story
February 11, 2022
SOURCE: Gilead Sciences
Via
3BL Media
What World Cancer Day Means to Me
February 09, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
February 08, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Living Well With Hepatitis B: Lai's Journey
February 08, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences Named a Best Place to Work for LGBTQ+ Equality in 2022
February 04, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences to Present at Upcoming Investor Conferences
February 03, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.